Clinical trials: Inhalation
Coronavirus Infection, COVID-19
Pulsed Inhaled Nitric Oxide for the Treatment of Patients With Mild or Moderate COVID-19
The search for novel therapies to address the ongoing coronavirus (COVID-19) pandemic is ongoing. No proven therapies have been identified to prevent progression of the virus.
- Conditions
- Coronavirus Infection, COVID-19, Pneumonia, Viral
- Trial name
- NCT04358588
- Testing
- iNO (inhaled nitric oxide) delivered via the INOpulse Delivery System
- Sponsor
- Bellerophon
Pulmonary Disease, Chronic Obstructive
To Evaluate the Safety, Tolerability, Pulmonary Deposition, Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Inhale in Japanese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD, GOLD II-III)
The study will be conducted in a single-center, randomized, single-blinded, placebo-controlled, dose escalation design with two dose groups.Multiple-dose inhalation of Ciprofloxacin inhale 50 and 75 mg or placebo will be…
- Trial name
- NCT01072942
- Testing
- Ciprofloxacin (Cipro InhaIe, BAYQ3939)
- Where
- Japan
- Volunteers
- 16 people
- Sponsor
- Bayer
Healthy
Comparative Pharmacokinetics and Pharmacodynamics of Tiotropium With Ipratropium or Placebo After 19 Days of Tiotropium Treatment
Comparative Pharmacokinetics and Pharmacodynamics of Tiotropium With Ipratropium or Placebo After 19 Days of Tiotropium Treatment
- Trial name
- NCT02172781
- Testing
- Ipratropium - unit dose vial, Tiotropium - inhalation capsule
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Asthma, COPD
Prospective evAluatIon foR Inhalation Devices Study
ASTHMA: Asthma is a chronic inflammatory disorder of the airways in which many different types of cells, and various cellular components.
- Trial name
- PAIR (NCT01800994)
- Where
- 6 sites in Greece
- Volunteers
- 750 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
RSV Infection
A Study To Evaluate the Safety of XW001 Inhalation in Children With RSV
This is a randomized, double-blind, placebo-controlled Phase Ib/IIa study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and immunogenicity of XW001 inhalation in children with RSV infection in China
- Trial name
- NCT05779995
- Testing
- XW001
- Where
- China
- Volunteers
- 61 people
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Chronic Obstructive Pulmonary Disease
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Doses of RV1729 for 28 Days in Patients With COPD
RV1729 is a new medicine being developed for the potential treatment of asthma and smoking related lung disease (also known as chronic obstructive pulmonary disease - COPD).
- Trial name
- NCT02140346
- Testing
- RV1729 28 day repeat dose
- Where
- 2 sites in United Kingdom
- Volunteers
- 48 people
- Sponsor
- Respivert Ltd
COPD (Chronic Obstructive Pulmonary Disease), Obesity Hypoventilation Syndrome (OHS)
Assessment of Breathing Pattern During NIV
COPD and OHS are respiratory conditions that disrupt normal breathing. Positive airway pressure, specifically Non-Invasive Ventilation (NIV), has been shown to improve breathing and reduce symptoms in patients with these…
- Trial name
- NCT06682286
- Testing
- NIV mask A, NIV mask B
- Where
- New Zealand
- Volunteers
- 40 people
- Sponsor
- Fisher and Paykel Healthcare
Asthma
Serial Lung Function Measurements in Healthy and Mild Asthmatic Adults After Oral Inhalation of Ethanolic Solutions Containing Two Concentrations of the Excipient Butylated Hydroxytoluene (BHT) Administered With the Respimat® B (RMT-B)
Primary objective: To investigate the safety and local tolerability of increasing cumulative doses (2, 4, 6 actuations) of a low (0.1%) and a high (0.5%) concentration of BHT administered via oral inhalation with the Respimat®…
- Trial name
- NCT02220673
- Testing
- BHT 0.1%, BHT 0.5%
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Volunteer
Study in Healthy Adults to Quantify Lung Deposition and Distribution of Radio-labelled S-770108 Inhalation Powder Formulation Delivered by a Novel Inhaler Device
The primary objective of this study is to assess the total lung deposition of radiolabelled S-770108 inhalation powder formulation after each of two separate single inhaled doses in healthy adult participants at two different…
- Trial name
- NCT04631354
- Testing
- Radio-labelled S-770108, S-770108 Inhaler A1
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Shionogi
Pulmonary Arterial Hypertension
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
The main objective of the study is to assess the effect of treprostinil palmitil inhalation powder (TPIP) compared with placebo on pulmonary vascular resistance.
- Trial name
- NCT05147805
- Testing
- Treprostinil Palmitil
- Where
- 92 sites in United States, Argentina and 15 more
- Volunteers
- 102 people
- Sponsor
- Insmed Incorporated
Asthma
A Study Comparing the Efficacy and Safety of CHF 1535 (BDP +FF) Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (BDP +FF), Administered Via a pMDI, in Moderate to Severe Asthma
To demonstrate that CHF 1535 via NEXT DPI (beclomethasone dipropionate + formoterol fumarate 100 + 6 μg), 1 inhalation or 2 inhalations twice daily, for 12 weeks is non-inferior to the corresponding dose of CHF 1535 via HFA-134a…
- Trial name
- NCT00862394
- Testing
- BDP/Formoterol Next DPI, Foster
- Where
- Germany
- Volunteers
- 783 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Healthy
Safety, Tolerability, Pharmacokinetics and Immunogenicity Study of GB002 Recombinant Peptide Inhalation Solution in Healthy Subjects
This trial is conducted in China. The purpose of this clinical trial is to evaluate the safety and tolerability, pharmacokinetic (PK) characteristics, and immunogenicity of single/multiple inhalation of different doses of GB002…
- Trial name
- NCT06423261
- Testing
- GB002 Recombinant Peptide Inhalation Solution
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Zhejiang Echon Biopharm Limited
Aspergillosis
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of PC945
PC945 is a new medicine being developed for treatment of fungal lung diseases. The main purpose of this study is to investigate the safety, tolerability and pharmacokinetics of single and repeat doses of PC945
- Trial name
- NCT02715570
- Testing
- PC945 - single doses, PC945 - repeat doses
- Where
- United Kingdom
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Pulmocide Ltd
Cystic Fibrosis
To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration
This is a Phase 1, first-in-human (FIH) single ascending dose study being conducted to better understand the safety, tolerability and pharmacokinetics of AZD5634 in healthy subjects
- Trial name
- NCT02679729
- Testing
- AZD5634 for inhalation, AZD5634 for infusion
- Where
- 2 sites in United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
A Study in Patients With Chronic Obstructive Pulmonary Disease
The primary objective of the study was to demonstrate the superiority of Foster® 100/6 (two puffs b.i.d.) versus Seretide® 500/50 (one inhalation b.i.d.), in terms of pulmonary function (AUC0-30min standardized by time of change…
- Trial name
- FUTURE (NCT01245569)
- Testing
- Beclomethasone Dipropionate - Formoterol, Fluticasone - Salmeterol
- Where
- 68 sites in Denmark, France and 8 more
- Volunteers
- 419 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Persistent Pulmonary Hypertension of the Newborn
Persistent Pulmonary Hypertension of the Newborn
The AC-052-391-study is a phase 3 study to investigate whether adding bosentan to inhaled nitric oxide in newborns with persistent pulmonary hypertension of newborns (PPHN) is a supporting and safe therapy and to evaluate the…
- Trial name
- FUTURE 4 (NCT01389856)
- Testing
- Bosentan
- Volunteers
- 23 people
- Sponsor
- Actelion
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety of Ba679BR Powder Inhalation in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Study to investigate the efficacy and safety of Ba679BR powder inhalation during the continuous once/day administration to the patients with COPD using oxitropium bromide (Tersigan® aerosol) as the comparator drug.
- Trial name
- NCT02172807
- Testing
- Tiotropium low, Tiotropium high, Oxitropium
- Volunteers
- 201 people
- Sponsor
- Boehringer Ingelheim
Covid19
A Phase 1, First-In-Human Study of the Investigational COVID-19 Vaccine SC-Ad6-1 in Healthy Volunteers
This is a single-centre, open-label, first-in-human, single ascending dose and multiple dose study to assess the safety, reactogenicity, and immunogenicity of the SC-Ad6-1 investigational product when administered via the…
- Trial name
- NCT04839042
- Testing
- SC-Ad6-1
- Where
- Australia
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- Moat Biotechnology Corporation
Asthma
Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study
The purpose of this study is to evaluate the long-term safety of fluticasone furoate/GW642444
- Trial name
- NCT01018186
- Testing
- Fluticasone Furoate/GW642444, Fluticasone propionate
- Where
- 47 sites in United States, Germany and 2 more
- Volunteers
- 503 people
- Sponsor
- GlaxoSmithKline
Allergic Asthma
The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen
AZD8848 is a new drug that is being tested for the treatment of asthma and allergic rhinitis (hayfever). This study will be in two parts and will include 59 asthmatic patients in total.
- Trial name
- NCT00999466
- Testing
- AZD8848
- Where
- 2 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.